Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Solvent-Mediated Control of Nanocellulose Dispersion: An Integrated Computational and Experimental Investigation.

ACS nano·2026

Same author

Author Correction: HLA polymorphisms shape divergent outcomes of Toxoplasma and Plasmodium infection in Eastern Indian HbE/β-thalassemia cohort.

Communications biology·2026

Same author

HLA polymorphisms shape divergent outcomes of Toxoplasma and Plasmodium infection in Eastern Indian HbE/β-thalassemia cohort.

Communications biology·2026

Same author

Restoration of neuromuscular function by mitochondrial transplantation in injured mouse skeletal muscle.

The Journal of physiology·2026

Same author

Anabolic resistance in cancer cachexia: a role for sex and chemotherapy.

Current opinion in clinical nutrition and metabolic care·2026

Same author

Targeting Quorum Sensing LsrR Protein in <i>E. coli:</i> A Computational Approach to Screen the Plant Bioactive Compounds as Inhibitors of Biofilm Formation in Urinary Tract Infections.

Assay and drug development technologies·2026

Search research articles

Related Experiment Video

Updated: Sep 13, 2025

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6.

Ankit Joshi¹, Zhousheng Xiao², Shreya Suman¹

¹Computational Biophysics Lab, Indian Institute of Technology (Indian School of Mines) Dhanbad, Dhanbad 826004, Jharkhand, India.

Molecules (Basel, Switzerland)

|July 30, 2025

Summary

Researchers screened for small-molecule inhibitors of human Interleukin-6 (hIL-6), a key inflammation mediator. One compound demonstrated significant inhibition of hIL-6 signaling, offering potential for new therapeutic strategies.

Keywords:

Human Interleukin-6 binding affinity ensemble docking inhibitors molecular dynamics small molecule antagonist

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Related Experiment Videos

Last Updated: Sep 13, 2025

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Area of Science:

Biochemistry
Molecular Biology
Computational Chemistry

Background:

Human Interleukin-6 (hIL-6) is a pro-inflammatory cytokine central to various diseases.
Current therapies involve monoclonal antibodies targeting hIL-6 or its receptor (IL-6Rα).
There is a need for alternative therapeutic modalities like small-molecule inhibitors.

Purpose of the Study:

To identify novel small-molecule antagonists of hIL-6 using computational screening.
To evaluate the therapeutic potential of identified compounds through in vitro assays.

Main Methods:

High-throughput structure-based computational screening utilizing ensemble docking.
Molecular dynamics simulations of the apo protein to generate target conformations.
Incorporation of prior knowledge on contact sites from experimental studies.
In vitro functional assays to validate computationally identified ligands.

Main Results:

Computational screening identified top-scoring small-molecule ligands.
One compound, with the second-highest binding affinity, exhibited an ~84% inhibition of IL6-induced STAT3 reporter activity at 10 μM.
This demonstrates significant in vitro efficacy of a computationally designed inhibitor.

Conclusions:

The study successfully identified a potent small-molecule inhibitor of hIL-6.
These findings support the development of small-molecule drugs targeting hIL-6 for therapeutic applications.
This approach may accelerate the discovery of new treatments for hIL-6-mediated diseases.